HSF1 and neoplasm: We show that targeting the DYRK2-HSF1 axis induces death in proteasome inhibitor-resistant cells and that dual loss of DYRK2 and HSF1 is indeed additive toward reducing TNBC tumour burden in ectopic and orthotopic xenograft models.